Inhibition of human intestinal wall metabolism by macrolide antibiotics: Effect of clarithromycin on cytochrome P450 3A4/5 activity and expression

Clinical Pharmacology and Therapeutics

Volumn 77, Issue 3, 2005, Pages 178-188

  Pinto, Amar G ^a   Wang, Ying Hong ^a   Chalasani, Naga ^a   Skaar, Todd ^a   Kolwankar, Dhanashri ^a   Gorski, J Christopher ^a   Liangpunsakul, Suthat ^a   Hamman, Mitchell A ^a   Arefayene, Million ^a   Hall, Stephen D ^a,b  

^a INDIANA UNIVERSITY   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYMIDAZOLAM; ALPHA HYDROXYMIDAZOLAM; CLARITHROMYCIN; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; DRUG METABOLITE; HYPNOTIC SEDATIVE AGENT; MACROLIDE; MESSENGER RNA; MIDAZOLAM; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; UNCLASSIFIED DRUG;

ADULT; ALLELE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; GENE EXPRESSION; GENOTYPE; HUMAN; HUMAN EXPERIMENT; HUMAN TISSUE; IMMUNOBLOTTING; INTESTINE BIOPSY; MALE; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SMALL INTESTINE MUCOSA; TISSUE LEVEL;

ADMINISTRATION, ORAL; ADULT; ARYL HYDROCARBON HYDROXYLASES; CLARITHROMYCIN; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; GENE EXPRESSION; GENOTYPE; HUMANS; INTESTINES; MALE; MIDAZOLAM; OXIDOREDUCTASES, N-DEMETHYLATING; TIME FACTORS;

EID: 13944250702     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clpt.2004.10.002     Document Type: Article

References (36)

1. M.G. Sturgill, R.P. Rapp Clarithromycin: review of a new macrolide antibiotic with improved microbiologic spectrum and favorable pharmacokinetic and adverse effect profiles Ann Pharmacother 26 1992 1099 1108
2. A. Markham, D. McTavish Clarithromycin and omeprazole as helicobacter pylori eradication therapy in patients with H. pylori-associated gastric disorders Drugs 51 1996 161 178
3. P.B. Watkins Drug metabolism by cytochromes P450 in the liver and small bowel Gastroenterol Clin North Am 21 1992 511 526
4. K.E. Thummel, G.R. Wilkinson In vitro and in vivo drug interactions involving human CYP3A Annu Rev Pharmacol Toxicol 38 1998 389 430
5. J.C. Gorski, D.R. Jones, B.D. Haehner-Daniels, M.A. Hamman, E.M. O'Mara Jr, S.D. Hall The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin Clin Pharmacol Ther 64 1998 133 143
6. B. Sadaba, dO. Lopez, J.R. Azanza, J. Quiroga, J.A. Cienfuegos Concurrent clarithromycin and cyclosporin A treatment J Antimicrob Chemother 42 1998 393 395
7. L.E. Gustavson, J.F. Kaiser, A.L. Edmonds, C.S. Locke, M.L. DeBartolo, D.W. Schneck Effect of omeprazole on concentrations of clarithromycin in plasma and gastric tissue at steady state Antimicrob Agents Chemother 39 1995 2078 2083
8. K. Wolter, K. Wagner, T. Philipp, E. Fritschka Interaction between FK 506 and clarithromycin in a renal transplant patient Eur J Clin Pharmacol 47 1994 207 208
9. B.S. Mayhew, D.R. Jones, S.D. Hall An in vitro model for predicting in vivo inhibition of cytochrome P450 3A4 by metabolic intermediate complex formation Drug Metab Dispos 28 2000 1031 1037
10. Y.H. Wang, D.R. Jones, S.D. Hall Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites Drug Metab Dispos 32 2004 259 266
11. K.E. Thummel, D.D. Shen, T.D. Podoll, K.L. Kunze, W.F. Trager, C.E. Bacchi Use of midazolam as a human cytochrome P450 3A probe II. Characterization of inter- and intraindividual hepatic CYP3A variability after liver transplantation J Pharmacol Exp Ther 271 1994 557 566
12. M.F. Paine, M. Khalighi, J.M. Fisher, D.D. Shen, K.L. Kunze, C.L. Marsh Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism J Pharmacol Exp Ther 283 1997 1552 1562
13. P. Kuehl, J. Zhang, Y. Lin, J. Lamba, M. Assem, J. Schuetz Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression Nat Genet 27 2001 383 391
14. E. Hustert, M. Haberl, O. Burk, R. Wolbold, Y.Q. He, K. Klein The genetic determinants of the CYP3A5 polymorphism Pharmacogenetics 11 2001 773 779
15. O.H. Lowry, N.H. Rosenbrough, A.L. Farr, F.J. Randall Protein measurement with Folin phenol reagent J Biol Chem 193 1951 265 275
16. A. Westlind, S. Malmebo, I. Johansson, C. Otter, T.B. Andersson, M. Ingelman-Sundberg Cloning and tissue distribution of a novel human cytochrome p450 of the CYP3A subfamily, CYP3A43 Biochem Biophys Res Commun 281 2001 1349 1355
17. Y.S. Lin, A.L. Dowling, S.D. Quigley, F.M. Farin, J. Zhang, J. Lamba Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism Mol Pharmacol 62 2002 162 172
18. K.S. Lown, J.C. Kolars, K.E. Thummel, J.L. Barnett, K.L. Kunze, S.A. Wrighton Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel Lack of prediction by the erythromycin breath test Drug Metab Dispos 22 1994 947 955
19. D.J. Belle, J.T. Callaghan, J.C. Gorski, J.F. Maya, O. Mousa, S.A. Wrighton The effects of an oral contraceptive containing ethinyloestradiol and norgestrel on CYP3A activity Br J Clin Pharmacol 53 2002 67 74
20. S.Y. Chu, D.S. Wilson, D.R. Guay, C. Craft Clarithromycin pharmacokinetics in healthy young and elderly volunteers J Clin Pharmacol 32 1992 1045 1049
21. T.C. Liu, S.F. Lin, T.P. Chen, J.G. Chang Polymorphism analysis of CYP3A5 in myeloid leukemia Oncol Rep 9 2002 327 329
22. R.H. van Schaik, I.P. van der Heiden, J.N. van den Anker, J. Lindemans CYP3A5 variant allele frequencies in Dutch Caucasians Clin Chem 48 2002 1668 1671
23. K.E. Thummel, D.D. Shen, T.D. Podoll, K.L. Kunze, W.F. Trager, P.S. Hartwell Use of midazolam as a human cytochrome P450 3A probe: I. In vitro-in vivo correlations in liver transplant patients J Pharmacol Exp Ther 271 1994 549 556
24. Y.S. Lin, G.F. Lockwood, M.A. Graham, W.R. Brian, C.M. Loi, M.R. Dobrinska In-vivo phenotyping for CYP3A by a single-point determination of midazolam plasma concentration Pharmacogenetics 11 2001 781 791
25. M. Jurima-Romet, K. Crawford, T. Cyr, T. Inaba Terfenadine metabolism in human liver In vitro inhibition by macrolide antibiotics and azole antifungals Drug Metab Dispos 22 1994 849 857
26. M. Tinel, V. Descatoire, D. Larrey, J. Loeper, G. Labbe, P. Letteron Effects of clarithromycin on cytochrome P-450 Comparison with other macrolides J Pharmacol Exp Ther 250 1989 746 751
27. S. Ohmori, I. Ishii, S. Kuriya, T. Taniguchi, T. Rikihisa, S. Hirose Effects of clarithromycin and its metabolites on the mixed function oxidase system in hepatic microsomes of rats Drug Metab Dispos 21 1993 358 363
28. P.B. Watkins, S.A. Wrighton, P. Maurel, E.G. Schuetz, G. Mendez-Picon, G.A. Parker Identification of an inducible form of cytochrome P-450 in human liver Proc Natl Acad Sci U S A 82 1985 6310 6314
29. D. Larrey, C. Funck-Brentano, P. Breil, J. Vitaux, C. Theodore, G. Babany Effects of erythromycin on hepatic drug-metabolizing enzymes in humans Biochem Pharmacol 32 1983 1063 1068
30. K.A. Hostetler, S.A. Wrighton, D.T. Molowa, P.E. Thomas, W. Levin, P.S. Guzelian Coinduction of multiple hepatic cytochrome P-450 proteins and their mRNAs in rats treated with imidazole antimycotic agents Mol Pharmacol 35 1989 279 285
31. S.A. Wrighton, C. Campanile, P.E. Thomas, S.L. Maines, P.B. Watkins, G. Parker Identification of a human liver cytochrome P-450 homologous to the major isosafrole-inducible cytochrome P-450 in the rat Mol Pharmacol 29 1986 405 410
32. K.S. Lown, D.G. Bailey, R.J. Fontana, S.K. Janardan, C.H. Adair, L.A. Fortlage Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression J Clin Invest 99 1997 2545 2553
33. O. von Richter, O. Burk, M.F. Fromm, K.P. Thon, M. Eichelbaum, K.T. Kivisto Cytochrome P450 3A4 and P-glycoprotein expression in human small intestinal enterocytes and hepatocytes: a comparative analysis in paired tissue specimens Clin Pharmacol Ther 75 2004 172 183
34. J.G. Blanco, M.J. Edick, M.L. Hancock, N.J. Winick, T. Dervieux, M.D. Amylon Genetic polymorphisms in CYP3A5, CYP3A4 and NQO1 in children who developed therapy-related myeloid malignancies Pharmacogenetics 12 2002 605 611
35. P.S. Shih, J.D. Huang Pharmacokinetics of midazolam and 1′-hydroxymidazolam in Chinese with different CYP3A5 genotypes Drug Metab Dispos 30 2002 1491 1496
36. I.A. Macphee, S. Fredericks, T. Tai, P. Syrris, N.D. Carter, A. Johnston Tacrolimus pharmacogenetics: polymorphisms associated with expression of cytochrome p4503A5 and P-glycoprotein correlate with dose requirement Transplantation 74 2002 1486 1489